UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 OF

THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of August 2024

 

Commission File Number 000-20181

 

SAPIENS INTERNATIONAL CORPORATION N.V.

(Translation of Registrants name into English)

 

Azrieli Center

26 Harokmim St.

Holon, 5885800 Israel

(Address of Principal Executive Office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F ☒      Form 40-F ☐

 

 

 

 

 

 

CONTENTS

 

Exhibit No.   Title of Exhibit
99.1   Press Release

 

1

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  Sapiens International Corporation N.V.
   
Date: August 1, 2024 By: /s/ Roni Giladi
    Name:  Roni Giladi
    Title: Chief Financial Officer

 

2

 

 

Exhibit Index

 

The following exhibit is furnished as part of this Form 6-K:

 

Exhibit   Description
99.1   Press Release

 

 

3

 

 

Exhibit 99.1

 

 

Sapiens Reports Second Quarter 2024 Financial Results

 

Rochelle Park, NJ, August 1, 2024 – Sapiens International Corporation, (NASDAQ and TASE: SPNS), a leading global provider of software solutions for the insurance industry, today announced its financial results for the second quarter ended June 30, 2024.

 

Summary Results for Second Quarter 2024 (USD in millions, except per share data)

 

   GAAP   Non-GAAP 
   Q2 2024   Q2 2023   % Change   Q2 2024   Q2 2023   % Change 
Revenue  $136.8   $128.3    6.6%  $136.8   $128.4    6.6%
Gross Profit  $60.1   $54.7    10.0%  $62.5   $58.0    7.7%
Gross Margin   43.9%   42.6%   130 bps    45.7%   45.2%   50 bps  
Operating Income  $21.9   $19.6    11.5%  $24.8   $23.4    6.1%
Operating Margin   16.0%   15.3%   70 bps    18.2%   18.2%   0 bps 
Net Income (*)  $18.6   $15.4    20.9%  $21.0   $18.6    13.1%
Diluted EPS  $0.33   $0.28    17.9%  $0.37   $0.33    12.1%

 

(*)Attributable to Sapiens’ shareholders

 

Roni Al-Dor, President and CEO of Sapiens, stated, “We are pleased to report that revenue reached $137 million this quarter, reflecting a 6.6% increase over the same period last year. This quarter demonstrated our strong execution capabilities, particularly with robust growth in North America and Europe. This quarter’s non-GAAP operating profit totaled $25 million, representing 18.2% of total revenue. Additionally, net income this quarter grew by 13%, and EPS per diluted share was $0.37 this quarter of 2024, up 12.1% from the second quarter of 2023”.

 

“We reiterate our 2024 guidance for non-GAAP revenues in a range of $550 million to $555 million and for non-GAAP operating margin in a range of 18.1%-18.5%,” concluded Mr. Al-Dor.

 

Quarterly Results Conference Call

 

Management will host a conference call and webcast on August 1, 2024, at 9:30 a.m. Eastern Time (4:30 p.m. in Israel) to review and discuss Sapiens’ results. Please call the following numbers (at least 10 minutes before the scheduled time) to participate:

 

North America (toll-free): 1-888-642-5032

 

International: 972-3-9180644

 

UK: 0-800-917-5108

 

The live webcast of the call can be viewed on Sapiens’ website at: https://veidan.activetrail.biz/sapiensq2-2024. A replay of the call will be available one business day following the completion of the event at the same link for 90 days.

 

 

 

 

Non-GAAP Financial Measures

 

This press release contains the following non-GAAP financial measures: non-GAAP revenue, ARR, non-GAAP gross profit, non-GAAP gross margin, non-GAAP operating income, non-GAAP operating margin, non-GAAP net income attributed to Sapiens shareholders, non-GAAP basic and diluted earnings per share, Adjusted EBITDA and Adjusted Free Cash-Flow.

 

Sapiens believes that these non-GAAP measures of financial results provide useful information to management and investors regarding certain financial and business trends relating to Sapiens’ financial condition and results of operations. The Company’s management uses these non-GAAP measures to compare the Company’s performance to that of prior periods for trend analyses, for purposes of determining executive and senior management incentive compensation and for budgeting and planning purposes. These measures are used in financial reports prepared for management and in quarterly financial reports presented to the Company’s board of directors. The Company believes that the use of these non-GAAP financial measures provides an additional tool for investors to use in evaluating ongoing operating results and trends, and in comparing the Company’s financial measures with other software companies, many of which present similar non-GAAP financial measures to investors.

 

Non-GAAP financial measures consist of GAAP financial measures adjusted to exclude: Valuation adjustment on acquired deferred revenue, amortization of capitalized software development and other intangible assets, capitalization of software development, stock-based compensation, compensation related to acquisition and acquisition-related costs, restructuring and cost reduction costs, and tax adjustments related to non-GAAP adjustments.

 

Management of the Company does not consider these non-GAAP measures in isolation, or as an alternative to financial measures determined in accordance with GAAP. The principal limitation of these non-GAAP financial measures is that they exclude significant expenses and income that are required by GAAP to be recorded in the Company’s financial statements. In addition, they are subject to inherent limitations, as they reflect the exercise of judgment by management about which expenses and income are excluded or included in determining these non-GAAP financial measures.

 

To compensate for these limitations, management presents non-GAAP financial measures in connection with GAAP results. Sapiens urges investors to review the reconciliation of its non-GAAP financial measures to the comparable GAAP financial measures, which it includes in press releases announcing quarterly financial results, including this press release, and not to rely on any single financial measure to evaluate the Company’s business.

 

2

 

 

Reconciliation tables of the most comparable GAAP financial measures to the non-GAAP financial measures used in this press release are included with the financial tables of this release.

 

The Company defines Annual Recurring Revenue (“ARR”) as the annualized value of our revenue from customer subscriptions, term licenses, maintenance, application maintenance, and cloud solutions, which may not be the same as the timing and amount of revenue recognized. The ARR run rate is equal to the product of (i) the sum of these revenues in our most recently completed fiscal quarter, multiplied by (ii) four.

 

The Company defines Adjusted EBITDA as net profit, adjusted to eliminate valuation adjustment on acquired deferred revenue, stock-based compensation expense, depreciation and amortization, capitalization of software development costs, compensation expenses related to acquisition and acquisition-related costs, restructuring and cost reduction costs, financial expense (income), provision for income taxes and other income (expenses). These amounts are often excluded by other companies as well, in order to help investors understand the operational performance of their business.

 

The Company uses Adjusted EBITDA as a measurement of its operating performance, because it assists in comparing the operating performance on a consistent basis by removing the impact of certain non-cash and non-operating items. Adjusted EBITDA reflects an additional way of viewing aspects of the operations that the Company believes, when viewed with the GAAP results and the accompanying reconciliations to corresponding GAAP financial measures, provide a more complete understanding of factors and trends affecting its business. The Company uses Adjusted Free Cash-Flow as a measurement of its operating performance, and reconciles cash-flow from operating activities to Adjusted Free Cash-Flow, while reducing the amounts for capitalization of software development costs and capital expenditures. The Company adds back cash payments made for former acquisitions in respect of future performance targets and retention criteria as determined upon acquisition date of the respective acquired company, which were included in the cash-flow from operating activities. We believe that Adjusted Free Cash-Flow is useful in evaluating our business, because Adjusted Free Cash-Flow reflects the cash surplus available to fund the expansion of our business.

 

3

 

 

About Sapiens

 

Sapiens International Corporation (NASDAQ and TASE: SPNS) empowers the financial sector, with a focus on insurance, to transform and become digital, innovative, and agile. With more than 40 years of industry expertise, Sapiens’ cloud-based SaaS insurance platform offers pre-integrated, low-code capabilities across core, data and digital domains to accelerate our customers’ digital transformation. Serving over 600 customers in more than 30 countries, Sapiens offers insurers across property and casualty, workers’ compensation, and life insurance markets the most comprehensive set of solutions, from core to complementary, including Reinsurance, Financial & Compliance, Data & Analytics, Digital, and Decision Management. For more information visit www.sapiens.com or follow us on LinkedIn.

 

Investor and Media Contact   Investor Contacts
     
Yaffa Cohen-Ifrah   Brett Maas
Chief Marketing Officer and Head of   Managing Partner, Hayden IR
Investor Relations, Sapiens   +1 646-536-7331
Yaffa.cohen-ifrah@sapiens.com   Brett.Maas@HaydenIR.com
+1 917-533-4782    
    Kimberly Rogers
    Managing Director, Hayden IR
    +1 541-904-5075
    kim@HaydenIR.com  

 

4

 

 

Forward Looking Statements

 

Certain matters discussed in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act, Section 21E of the Exchange Act and the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, and are based on our beliefs, assumptions and expectations, as well as information currently available to us. Such forward-looking statements may be identified by the use of the words “anticipate,” “believe,” “estimate,” “expect,” “may,” “will,” “plan” and similar expressions. Such statements reflect our current views with respect to future events and are subject to certain risks and uncertainties. There are important factors that could cause our actual results, levels of activity, performance or achievements to differ materially from the results, levels of activity, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to: the degree of our success in our plans to leverage our global footprint to grow our sales; the degree of our success in integrating the companies that we have acquired through the implementation of our M&A growth strategy; the lengthy development cycles for our solutions, which may frustrate our ability to realize revenues and/or profits from our potential new solutions; our lengthy and complex sales cycles, which do not always result in the realization of revenues; the degree of our success in retaining our existing customers or competing effectively for greater market share; difficulties in successfully planning and managing changes in the size of our operations; the frequency of the long-term, large, complex projects that we perform that involve complex estimates of project costs and profit margins, which sometimes change mid-stream; the challenges and potential liability that heightened privacy laws and regulations pose to our business; occasional disputes with clients, which may adversely impact our results of operations and our reputation; various intellectual property issues related to our business; potential unanticipated product vulnerabilities or cybersecurity breaches of our or our customers’ systems; risks related to the insurance industry in which our clients operate; risks associated with our global sales and operations, such as changes in regulatory requirements, wide-spread viruses and epidemics like the recent novel coronavirus pandemic, which adversely affected our results of operations, or fluctuations in currency exchange rates; and risks related to our principal location in Israel and our status as a Cayman Islands company. While we believe such forward-looking statements are based on reasonable assumptions, should one or more of the underlying assumptions prove incorrect, or these risks or uncertainties materialize, our actual results may differ materially from those expressed or implied by the forward-looking statements. Please read the risks discussed under the heading “Risk Factors” in our most recent Annual Report on Form 20-F, which we filled with the SEC on March 31, 2022, in order to review conditions that we believe could cause actual results to differ materially from those contemplated by the forward-looking statements. You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that future results, levels of activity, performance and events and circumstances reflected in the forward-looking statements will be achieved or will occur. Except as required by law, we undertake no obligation to update publicly any forward-looking statements for any reason, to conform these statements to actual results or to changes in our expectations.

 

5

 

 

SAPIENS INTERNATIONAL CORPORATION N.V. AND ITS SUBSIDIARIES

 

CONDENSED CONSOLIDATED STATEMENT OF INCOME

U.S. dollars in thousands (except per share amounts)

 

   Three months ended   Six months ended 
   June 30,   June 30, 
   2024   2023   2024   2023 
   (unaudited)   (unaudited)   (unaudited)   (unaudited) 
                 
Revenue   136,800    128,299    271,049    253,020 
Cost of revenue   76,696    73,635    153,385    145,327 
                     
Gross profit   60,104    54,664    117,664    107,693 
                     
Operating expenses:                    
Research and development, net   16,809    15,746    33,330    31,363 
Selling, marketing, general and administrative   21,412    19,297    41,929    37,816 
Total operating expenses   38,221    35,043    75,259    69,179 
                     
Operating income   21,883    19,621    42,405    38,514 
                     
Financial and other expenses (income), net   (1,109)   562    (2,201)   1,759 
Taxes on income   4,375    3,587    8,488    6,917 
                     
Net income   18,617    15,472    36,118    29,838 
                     
Attributable to non-controlling interest   -    69    141    239 
                     
Net income attributable to Sapiens’ shareholders   18,617    15,403    35,977    29,599 
                     
Basic earnings per share   0.33    0.28    0.65    0.54 
                     
Diluted earnings per share   0.33    0.28    0.64    0.53 
                     
Weighted average number of shares outstanding used to compute basic earnings per share (in thousands)   55,797    55,196    55,771    55,176 
                     
Weighted average number of shares outstanding used to compute diluted earnings per share (in thousands)   56,163    55,582    56,072    55,576 

 

6

 

 

SAPIENS INTERNATIONAL CORPORATION N.V. AND SUBSIDIARIES

 

RECONCILIATION OF GAAP TO NON-GAAP RESULTS

U.S. dollars in thousands (except per share amounts)

 

   Three months ended   Six months ended 
   June 30,   June 30, 
   2024   2023   2024   2023 
   (unaudited)   (unaudited)   (unaudited)   (unaudited) 
                 
GAAP revenue   136,800    128,299    271,049    253,020 
Valuation adjustment on acquired deferred revenue   -    55    -    110 
Non-GAAP revenue   136,800    128,354    271,049    253,130 
                     
GAAP gross profit   60,104    54,664    117,664    107,693 
Revenue adjustment   -    55    -    110 
Amortization of capitalized software   1,569    1,425    3,114    2,856 
Amortization of other intangible assets   808    1,848    2,587    3,696 
Non-GAAP gross profit   62,481    57,992    123,365    114,355 
                     
GAAP operating income   21,883    19,621    42,405    38,514 
Gross profit adjustments   2,377    3,328    5,701    6,662 
Capitalization of software development   (1,823)   (1,679)   (3,540)   (3,337)
Amortization of other intangible assets   1,223    1,084    2,456    2,160 
Stock-based compensation   811    1,059    1,583    1,922 
Acquisition-related costs *)   365    4    494    10 
Non-GAAP operating income   24,836    23,417    49,099    45,931 
                     
GAAP net income attributable to Sapiens’ shareholders   18,617    15,403    35,977    29,599 
Operating income adjustments   2,953    3,796    6,694    7,417 
Taxes on income   (529)   (589)   (1,209)   (1,153)
Non-GAAP net income attributable to Sapiens’ shareholders   21,041    18,610    41,462    35,863 

 

(*) Acquisition-related costs pertain to charges on behalf of M&A agreements related to future performance targets and retention criteria, as well as completed or prospective third-party services, such as tax, accounting and legal rendered.

 

7

 

 

Adjusted EBITDA Calculation
U.S. dollars in thousands

 

   Three months ended   Six months ended 
   June 30,   June 30, 
   2024   2023   2024   2023 
                 
GAAP operating profit   21,883    19,621    42,405    38,514 
                     
Non-GAAP adjustments:                    
Valuation adjustment on acquired deferred revenue   -    55    -    110 
Amortization of capitalized software   1,569    1,425    3,114    2,856 
Amortization of other intangible assets   2,031    2,932    5,043    5,856 
Capitalization of software development   (1,823)   (1,679)   (3,540)   (3,337)
Stock-based compensation   811    1,059    1,583    1,922 
Compensation related to acquisition and acquisition-related costs   365    4    494    10 
                     
Non-GAAP operating profit   24,836    23,417    49,099    45,931 
                     
Depreciation   1,095    976    2,192    2,031 
                     
Adjusted EBITDA   25,931    24,393    51,291    47,962 

 

Summary of NON-GAAP Financial Information
U.S. dollars in thousands (except per share amounts)

 

   Q2 2024   Q1 2024   Q4 2023   Q3 2023   Q2 2023 
                     
Revenues   136,800    134,249    130,914    130,760    128,354 
Gross profit   62,481    60,884    59,370    59,260    57,992 
Operating income   24,836    24,263    24,152    24,058    23,417 
Adjusted EBITDA   25,931    25,360    25,267    24,777    24,393 
Net income to Sapiens’ shareholders   21,041    20,421    20,081    19,080    18,610 
                          
Diluted earnings per share   0.37    0.36    0.36    0.34    0.33 

 

Annual Recurring Revenue (“ARR”)

U.S. dollars in thousands 

 

Three months ended June 30, 
2024   2023 
 168,593    150,417 

 

8

 

 

Non-GAAP Revenues by Geographic Breakdown
U.S. dollars in thousands

 

   Q2 2024   Q1 2024   Q4 2023   Q3 2023   Q2 2023 
                     
North America   57,918    55,158    54,882    54,848    52,116 
Europe   66,072    68,727    65,239    64,662    62,960 
Rest of the World   12,810    10,364    10,793    11,250    13,278 
                          
Total   136,800    134,249    130,914    130,760    128,354 

 

Non-GAAP Revenue breakdown

U.S. dollars in thousands

 

   Three months ended   Six months ended 
   June 30,   June 30, 
   2024   2023   2024   2023 
                 
Software products and re-occurring post-production services (*)   98,044    82,559    192,285    164,401 
Pre-production implementation services (**)   38,756    45,795    78,764    88,729 
                     
Total Revenues   136,800    128,354    271,049    253,130 

 

   Three months ended   Six months ended 
   June 30,   June 30, 
   2024   2023   2024   2023 
                 
Software products and re-occurring post-production services (*)   52,237    42,437    102,577    87,286 
Pre-production implementation services (**)   10,244    15,555    20,788    27,069 
                     
Total Gross profit   62,481    57,992    123,365    114,355 

 

   Three months ended   Six months ended 
   June 30,   June 30, 
   2024   2023   2024   2023 
                 
Software products and re-occurring post-production services (*)   53.3%   51.4%   53.3%   53.1%
Pre-production implementation services (**)   26.4%   34.0%   26.4%   30.5%
                     
Gross Margin   45.7%   45.2%   45.5%   45.2%

 

(*)Software products and re-occurring post-production services include mainly subscription, term license, maintenance, application maintenance, cloud solutions and post-production services. This revenue stream is a mix of recurring and re-occurring in nature.

 

(**)Pre-production implementation services include mainly implementation services before go-live, which are one-time in nature.

 

9

 

 

Adjusted Free Cash-Flow
U.S. dollars in thousands

 

   Q2 2024   Q1 2024   Q4 2023   Q3 2023   Q2 2023 
                     
Cash-flow from operating activities   8,545    18,488    38,646    3,988    14,603 
Increase in capitalized software development costs   (1,823)   (1,717)   (1,543)   (1,638)   (1,679)
Capital expenditures   (666)   (466)   (421)   (696)   (775)
Free cash-flow   6,056    16,305    36,682    1,654    12,149 
                          
Cash payments attributed to acquisition-related costs(*) (**)   134    751    221    -    - 
                          
Adjusted free cash-flow   6,190    17,056    36,903    1,654    12,149 

 

(*)Included in cash-flow from operating activities

 

(**) Acquisition-related payments pertain to charges on behalf of M&A agreements related to future performance targets and retention criteria, as well as completed or prospective third-party services, such as tax, accounting and legal rendered.

 

10

 

 

SAPIENS INTERNATIONAL CORPORATION N.V. AND ITS SUBSIDIARIES

 

CONDENSED CONSOLIDATED BALANCE SHEET

U.S. dollars in thousands

 

   June 30,   December 31, 
   2024   2023 
   (unaudited)   (unaudited) 
         
ASSETS        
         
CURRENT ASSETS        
Cash and cash equivalents   122,646    126,716 
Short-term bank deposit   63,800    75,400 
Trade receivables, net and unbilled receivables   102,101    90,273 
Other receivables and prepaid expenses   20,258    22,514 
Total current assets   308,805    314,903 
           
LONG-TERM ASSETS          
Property and equipment, net   12,065    12,661 
Severance pay fund   3,360    3,605 
Goodwill and intangible assets, net   307,231    317,352 
Operating lease right-of-use assets   20,505    23,557 
Other long-term assets   15,571    17,546 
Total long-term assets   358,732    374,721 
           
TOTAL ASSETS   667,537    689,624 
LIABILITIES AND EQUITY          
           
CURRENT LIABILITIES          
Trade payables   11,296    6,291 
Current maturities of Series B Debentures   19,796    19,796 
Accrued expenses and other liabilities   74,057    77,873 
Current maturities of operating lease liabilities   5,705    6,623 
Deferred revenue   31,928    38,541 
Total current liabilities   142,782    149,124 
           
LONG-TERM LIABILITIES          
Series B Debentures, net of current maturities   19,768    39,543 
Deferred tax liabilities   8,517    10,820 
Other long-term liabilities   11,469    11,538 
Long-term operating lease liabilities   17,816    21,084 
Accrued severance pay   7,443    7,568 
Total long-term liabilities   65,013    90,553 
           
EQUITY   459,742    449,947 
           
TOTAL LIABILITIES AND EQUITY   667,537    689,624 

 

11

 

 

SAPIENS INTERNATIONAL CORPORATION N.V. AND ITS SUBSIDIARIES

 

CONSOLIDATED STATEMENT OF CASH FLOW
U.S. dollars in thousands

 

   For the six months ended
June 30,
 
   2024   2023 
   (unaudited)   (unaudited) 
Cash flows from operating activities:        
Net income   36,118    29,838 
Reconciliation of net income to net cash provided by operating activities:          
Depreciation and amortization   10,349    10,743 
Accretion of discount on Series B Debentures   22    32 
Capital (gain) loss from sale of property and equipment   (9)   86 
Stock-based compensation related to options issued to employees   1,583    1,922 
           
Net changes in operating assets and liabilities, net of amount acquired:          
Decrease (increase) in trade receivables, net and unbilled receivables   (12,723)   2,351 
Increase (decrease) in deferred tax liabilities, net   (1,428)   45 
Decrease (increase) in other operating assets   3,445    (390)
Increase (decrease) in trade payables   4,446    (1,014)
Decrease in other operating liabilities   (8,354)   (12,572)
Increase (decrease) in deferred revenues   (6,587)   5,284 
Increase in accrued severance pay, net   171    466 
Net cash provided by operating activities   27,033    36,791 
           
Cash flows from investing activities:          
Purchase of property and equipment   (1,146)   (1,439)
Proceeds from (investment in) deposits   12,136    (70,002)
Proceeds from sale of property and equipment   14    30 
Payments for business acquisitions, net of cash acquired   (375)   - 
Capitalized software development costs   (3,540)   (3,337)
Acquisition of intellectual property   -    (177)
Net cash provided by (used in) investing activities   7,089    (74,925)
           
Cash flows from financing activities:          
Proceeds from employee stock options exercised   98    - 
Distribution of dividend   (15,635)   (13,796)
Repayment of Series B Debenture   (19,796)   (19,796)
Acquisition of non-controlling interest   (4,131)   - 
Dividend to non-controlling interest   -    (47)
Net cash used in financing activities   (39,464)   (33,639)
           
Effect of exchange rate changes on cash and cash equivalents   1,272    905 
           
Decrease in cash and cash equivalents   (4,070)   (70,868)
Cash and cash equivalents at the beginning of period   126,716    160,285 
           
Cash and cash equivalents at the end of period   122,646    89,417 

 

12

 

 

Debentures Covenants

 

As of June 30, 2024, Sapiens was in compliance with all of its financial covenants under the indenture for the Series B Debentures, based on having achieved the following in its consolidated financial results:

 

Covenant 1

 

§Target shareholders’ equity (excluding non-controlling interest): above $120 million.

 

§Actual shareholders’ equity (excluding non-controlling interest) equal to $459.7 million.

 

Covenant 2

 

§Target ratio of net financial indebtedness to net capitalization (in each case, as defined under the indenture for the Company’s Series B Debentures) below 65%.

 

§Actual ratio of net financial indebtedness to net capitalization equal to (46.79)%.

 

Covenant 3

 

§Target ratio of net financial indebtedness to EBITDA (accumulated calculation for the four last quarters) is below 5.5.

 

§Actual ratio of net financial indebtedness to EBITDA (accumulated calculation for the four last quarters) is equal to (1.45).

 

 

13

 


Sapiens International Co... (NASDAQ:SPNS)
Historical Stock Chart
From Jul 2024 to Aug 2024 Click Here for more Sapiens International Co... Charts.
Sapiens International Co... (NASDAQ:SPNS)
Historical Stock Chart
From Aug 2023 to Aug 2024 Click Here for more Sapiens International Co... Charts.